Shanghai Jiao Tong Probes Trial After 6-Year-Old Dies in $800,000 Genome-Editing Case
Updated
Updated · BioNews · Aug 4
Shanghai Jiao Tong Probes Trial After 6-Year-Old Dies in $800,000 Genome-Editing Case
3 articles · Updated · BioNews · Aug 4
Summary
A six-year-old girl died within a week of receiving an experimental base-editing treatment at Xinhua Hospital in March 2025, and Shanghai Jiao Tong University has now opened an investigation into the single-patient trial.
Science and Retraction Watch reported the therapy used adeno-associated viruses delivered into spinal fluid to target a brain-development mutation; experts said the likely cause was virus overload triggering a severe immune reaction.
More than $800,000 from the girl's parents helped fund the therapy and related animal work, and the investigation raised questions about whether they were given enough information to provide fully informed consent.
A Nature paper on the animal research omitted that all four treated macaques developed moderate-to-severe liver damage and that a child had already received the therapy and died; the journal has added an editor's note.
The case has revived scrutiny of China's oversight of experimental genome editing, though new biomedical-technology rules now in force may tighten ethics review, consent and clinical governance.
How did a child die after a custom genome-editing treatment despite severe macaque toxicity—and why wasn’t it disclosed earlier?
Is this Shanghai tragedy a warning that genome-editing science is advancing faster than consent, transparency, and immune-safety oversight?
Death, Disclosure, and Dollars: The 2026 Shanghai Gene-Editing Scandal and Its Global Impact on Ethics, Regulation, and Scientific Trust
Overview
In 2025, a six-year-old girl named Mei died after receiving an experimental gene-editing treatment at Xinhua Hospital, funded largely by her parents. Despite clear preclinical warnings of severe side effects, the trial was rushed under a regulatory loophole that allowed investigator-initiated studies to bypass national oversight. Mei’s death was kept secret for over a year, while the research team published a paper omitting the human trial and her death. Public exposure in 2026 led to global outrage, formal investigations, and highlighted deep flaws in China’s biomedical oversight, ultimately prompting major regulatory reforms and damaging international trust in Chinese research.